Literature DB >> 18765146

Adolescent issues in migraine: a focus on menstrual migraine.

Christine L Lay1, Susan W Broner.   

Abstract

Migraine commonly affects adolescents, and menstrual migraine often begins in young girls. If undiagnosed or ineffectively treated, migraine can lead to disability, school absenteeism, emotional or social difficulties, and chronification of headache. Thus, recognizing and accurately diagnosing migraine and menstrual migraine, developing effective treatment strategies (both pharmacologic and nonpharmacologic), and educating both the adolescent and her parents are important in order to minimize the potential early disability of this disorder and limit the otherwise likely progression of migraine to a disabling disorder of adulthood.

Entities:  

Mesh:

Year:  2008        PMID: 18765146     DOI: 10.1007/s11916-008-0065-7

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  28 in total

Review 1.  Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review.

Authors:  Elizabeth W Loder; Dawn C Buse; Joan R Golub
Journal:  Am J Obstet Gynecol       Date:  2005-09       Impact factor: 8.661

2.  Migraine and oral contraceptives.

Authors:  K Dalton
Journal:  Headache       Date:  1976-01       Impact factor: 5.887

3.  Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study.

Authors:  G Sances; E Martignoni; L Fioroni; F Blandini; F Facchinetti; G Nappi
Journal:  Headache       Date:  1990-11       Impact factor: 5.887

4.  Use of the ICHD-II criteria in the diagnosis of pediatric migraine.

Authors:  Andrew D Hershey; Paul Winner; Marielle A Kabbouche; Jack Gladstein; Marcy Yonker; Don Lewis; Eric Pearlman; Steven L Linder; A David Rothner; Scott W Powers
Journal:  Headache       Date:  2005 Nov-Dec       Impact factor: 5.887

Review 5.  Practice guideline for diagnosis and management of migraine headaches in children and adolescents: part one.

Authors:  Kathy B Gunner; Holly D Smith
Journal:  J Pediatr Health Care       Date:  2007 Sep-Oct       Impact factor: 1.812

6.  Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo.

Authors:  N S Al-Waili
Journal:  Eur J Med Res       Date:  2000-04-19       Impact factor: 2.175

Review 7.  The global burden of headache: a documentation of headache prevalence and disability worldwide.

Authors:  Lj Stovner; K Hagen; R Jensen; Z Katsarava; Rb Lipton; Ai Scher; Tj Steiner; J-A Zwart
Journal:  Cephalalgia       Date:  2007-03       Impact factor: 6.292

8.  Chronic daily headache in French children and adolescents.

Authors:  Jean-Christophe Cuvellier; Frédéric Couttenier; Sylvie Joriot-Chekaf; Louis Vallée
Journal:  Pediatr Neurol       Date:  2008-02       Impact factor: 3.372

9.  A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.

Authors:  Stephen D Silberstein; Arthur H Elkind; Curtis Schreiber; Charlotte Keywood
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

10.  Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.

Authors:  Steven L Linder; Ninan T Mathew; Roger K Cady; Gary Finlayson; Gary Ishkanian; Donald W Lewis
Journal:  Headache       Date:  2008-05-14       Impact factor: 5.887

View more
  3 in total

Review 1.  Women and Migraine: the Role of Hormones.

Authors:  Candice Todd; Ana Marissa Lagman-Bartolome; Christine Lay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-31       Impact factor: 5.081

Review 2.  Epidemiology of migraine and headache in children and adolescents.

Authors:  Ciçek Wöber-Bingöl
Journal:  Curr Pain Headache Rep       Date:  2013-06

3.  Epidemiological and clinical characteristics of primary headaches in adolescent population: is there a relationship with the way of life?

Authors:  Ines Mlinarevic-Polic; Zdravko Kuzman; Ivan Aleric; Darko Katalinic; Aleksandar Vcev; Vlasta Duranovic
Journal:  Acta Neurol Belg       Date:  2019-10-24       Impact factor: 2.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.